Wegovy goes subscription; Rybelsus rebrand

Novo Nordisk is turning Wegovy into a subscription product, tying the blockbuster weight-loss drug more tightly to telehealth platforms and monthly pricing. (prnewswire.com) The program began March 31, 2026, through Ro, WeightWatchers, and LifeMD for eligible self-pay patients, with Hims & Hers, Sesame, and other providers slated to join later. Novo Nordisk said longer plans lower the monthly price and can save some patients up to $1,200 a year on injectable Wegovy. (cnbc.com) Wegovy is semaglutide, a drug that mimics a gut hormone to curb appetite and slow stomach emptying, and it is approved for chronic weight management and to cut cardiovascular risk in some adults with obesity. Novo Nordisk said the subscription keeps the monthly price flat even when a patient changes dose. (prnewswire.com) Novo Nordisk is also collapsing another semaglutide brand name. On February 4, 2026, the company said oral semaglutide tablets previously sold as Rybelsus would be marketed as Ozempic tablets in the United States starting in the second quarter of 2026. (drugs.com) The pill is not a new molecule. The FDA-approved tablets contain semaglutide in 1.5 milligram, 4 milligram, and 9 milligram doses for adults with type 2 diabetes, and the name change aligns them with the better-known Ozempic injection brand. (epocrates.com) Trade publications and pharmacy benefit analysts said the rebrand is aimed at recognition and paperwork as much as marketing. HCP Live reported that Novo Nordisk expects the Ozempic name to reduce confusion and smooth prior authorization requests that previously referred to the injectable brand while the oral product carried the Rybelsus name. (hcplive.com) Taken together, the two moves put the same semaglutide franchise into two simpler channels: recurring telehealth subscriptions for obesity care and a single Ozempic label for diabetes tablets and injections. That gives Novo Nordisk a cleaner sales pitch as Eli Lilly presses its own obesity and diabetes drugs across clinics, direct-pay programs, and new pill launches. (cnbc.com) The subscription rollout also lands after months of tension over compounded copies and online prescribing. Medscape reported that some experts welcomed lower predictable pricing for self-pay patients but warned that obesity care routed through multiple telehealth vendors can fragment follow-up and side-effect management. (medscape.com) WeightWatchers, one of the launch partners, said the new pricing strengthens its role as a NovoCare recognized provider for GLP-1 treatment. Novo Nordisk is betting that easier payment and fewer brand names will keep semaglutide patients inside its own network longer. (corporate.ww.com)